EXEL Exelixis Inc

$38.71

*Only the 1D chart reflects 15-min delayed quotes during market hours. Other timeframes update after market close.

Reporting for fiscal period ending —
Expected on —
Report Time: Unknown Release Time
The Whisper Number
—
Consensus Estimate: —
Revenue Estimate: —

Latest Earnings Insight

Updated On 8/22/2025

About Exelixis Inc

Exelixis, Inc., an oncology-focused biotechnology company, is focused on the discovery, development, and commercialization of new drugs to treat cancers in the United States. The company is headquartered in Alameda, California.

Website: https://www.exelixis.com

Sector
TRADE & SERVICES
Industry
SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH
Exchange
NASDAQ
Country
USA
Currency
USD
Fiscal Year End
December
CIK
939767
Address
1851 HARBOR BAY PARKWAY, ALAMEDA, CA, US
Valuation
Market Cap
$9.97B
P/E Ratio
20.56
PEG Ratio
2.27
Price to Book
4.44
Performance
EPS
$1.76
Dividend Yield
—
Profit Margin
24.00%
ROE
23.10%
Technicals
50D MA
$36.30
200D MA
$31.23
52W High
$40.02
52W Low
$20.14
Fundamentals
Shares Outstanding
276M
Target Price
$37.95
Beta
0.57

EXEL EPS Estimates vs Actual

● Estimated
● Actual

EXEL News & Sentiment

Aug 19, 2025 • Zacks Commentary SOMEWHAT-BULLISH
Will EXEL's Share Repurchase Program Boost Value for Investors?
Exelixis repurchases shares for $796M, aiming to boost EPS and shareholder value through 2025.
Aug 18, 2025 • Zacks Commentary BULLISH
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Aug 17, 2025 • Benzinga NEUTRAL
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Exelixis, Inc. - EXEL - Exelixis ( NASDAQ:EXEL )
NEW YORK, Aug. 17, 2025 ( GLOBE NEWSWIRE ) -- Pomerantz LLP is investigating claims on behalf of investors of Exelixis, Inc. ( "Exelixis" or the "Company" ) EXEL. Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
Aug 14, 2025 • Zacks Commentary SOMEWHAT-BULLISH
Exelixis Gains 15.6% YTD: How Should You Play the Stock?
EXEL rides on Cabometyx growth and zanzalintinib's trial success, but Q2 revenue miss and competition keep investor sentiment cautious.
Aug 13, 2025 • Zacks Commentary SOMEWHAT-BULLISH
Will Zanzalintinib Ease Out EXEL's Reliance on Cabometyx for Growth?
Exelixis reports strong phase III results for zanzalintinib in metastatic colorectal cancer, raising hopes beyond Cabometyx.
Aug 13, 2025 • Zacks Commentary BULLISH
Is First Trust Health Care AlphaDEX ETF ( FXH ) a Strong ETF Right Now?
Smart Beta ETF report for ...
Sentiment Snapshot

Average Sentiment Score:

0.258
50 articles with scored sentiment

Overall Sentiment:

Bullish

EXEL Reported Earnings

Apr 28, 2025
Mar 31, 2025 (Pre market)
0.0 Surprise
  • Reported EPS: $0.00
  • Estimate: $0.37
  • Whisper: —
  • Surprise %: 0.0%
Feb 04, 2025
Dec 31, 2024 (Pre market)
0.06 Surprise
  • Reported EPS: $0.55
  • Estimate: $0.49
  • Whisper: —
  • Surprise %: 11.8%
Oct 29, 2024
Sep 30, 2024 (Post market)
0.05 Surprise
  • Reported EPS: $0.40
  • Estimate: $0.35
  • Whisper: —
  • Surprise %: 14.3%
Aug 06, 2024
Jun 30, 2024 (Post market)
0.47 Surprise
  • Reported EPS: $0.77
  • Estimate: $0.30
  • Whisper: —
  • Surprise %: 156.7%
Apr 30, 2024
Mar 31, 2024 (Post market)
-0.04 Surprise
  • Reported EPS: $0.20
  • Estimate: $0.24
  • Whisper: —
  • Surprise %: -16.7%
Feb 06, 2024
Dec 31, 2023 (Post market)
0.06 Surprise
  • Reported EPS: $0.27
  • Estimate: $0.21
  • Whisper: —
  • Surprise %: 28.6%
Nov 01, 2023
Sep 30, 2023 (Post market)
0.0 Surprise
  • Reported EPS: $0.10
  • Estimate: $0.10
  • Whisper: —
  • Surprise %: 0.0%
Aug 01, 2023
Jun 30, 2023 (Post market)
0.09 Surprise
  • Reported EPS: $0.25
  • Estimate: $0.16
  • Whisper: —
  • Surprise %: 56.2%
May 09, 2023
Mar 31, 2023 (Post market)
-0.03 Surprise
  • Reported EPS: $0.12
  • Estimate: $0.15
  • Whisper: —
  • Surprise %: -20.0%

Financials